Fig 2.

PK/PD of Flt3L-Fc in NHPs administered Flt3L-Fc in combination with the artPICV/artLCMV vaccine. (A) Schematic of study design. (B) Serum concentration of Flt3L-Fc in rhesus during study. (C) AUC for Flt3L-Fc exposure after each dose. (D) Fold change in cDC1s in peripheral blood measured by whole blood flow cytometry 7 days after Flt3L-Fc dosing during the study relative to baseline. (E) Fold change in median fluorescence intensity (MFI) of activation marker CD86 on cDC1. (F) Monocytes in peripheral blood were quantified by complete blood count analysis. N = 13/group. Data are median ± interquartile range (IQR). *P < 0.05, **P < 0.01, ****P < 0.0001. Friedman’s test (one-way ANOVA with repeated measures) with Dunn’s post-test for multiple comparisons in D and E, and Kruskal–Wallis test with Dunn’s post-test for multiple comparisons in F.